دورية أكاديمية
Pharmacogenetics of oral antidiabetic therapy.
| العنوان: | Pharmacogenetics of oral antidiabetic therapy. |
|---|---|
| المؤلفون: | Ordelheide AM; Institute for Diabetes Research & Metabolic Diseases of the Helmholtz Centre Munich at the Eberhard Karls University Tübingen, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany., Hrabě de Angelis M; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.; Chair for Experimental Genetics, Technical University Munich, Neuherberg, Germany., Häring HU; Institute for Diabetes Research & Metabolic Diseases of the Helmholtz Centre Munich at the Eberhard Karls University Tübingen, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Department of Internal Medicine IV, Division of Endocrinology, Diabetology, Angiology, Nephrology & Clinical Chemistry, University Hospital Tübingen, Germany.; Interfaculty Center for Pharmacogenomics & PharmaResearch at the Eberhard Karls University Tübingen, Germany., Staiger H; Institute for Diabetes Research & Metabolic Diseases of the Helmholtz Centre Munich at the Eberhard Karls University Tübingen, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Interfaculty Center for Pharmacogenomics & PharmaResearch at the Eberhard Karls University Tübingen, Germany.; Institute of Pharmaceutical Sciences, Department of Pharmacy & Biochemistry, Eberhard Karls University Tübingen, Germany. |
| المصدر: | Pharmacogenomics [Pharmacogenomics] 2018 Apr; Vol. 19 (6), pp. 577-587. Date of Electronic Publication: 2018 Mar 27. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 100897350 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8042 (Electronic) Linking ISSN: 14622416 NLM ISO Abbreviation: Pharmacogenomics Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Future Medicine Ltd Original Publication: London : Ashley Publications, |
| مواضيع طبية MeSH: | Pharmacogenetics*, Diabetes Mellitus, Type 2/*drug therapy , Insulin/*genetics , Metformin/*therapeutic use, Administration, Oral ; Diabetes Mellitus, Type 2/genetics ; Humans ; Hypoglycemic Agents/therapeutic use ; Metformin/adverse effects |
| مستخلص: | Type 2 diabetes prevalence is still on the rise worldwide. Antidiabetic drugs are widely prescribed to patients with Type 2 diabetes. Most patients start with metformin which is mostly well tolerated. However, a high percentage of patients fail to achieve glycemic control. The effectiveness of metformin as well as most other antidiabetic drugs depends among other factors on interindividual genetic differences that are up to now ignored in the treatment of Type 2 diabetes. Interestingly, many genes influencing the effectiveness of antidiabetic drugs are Type 2 diabetes risk genes making matters worse. Here, we shed light on these interindividual genetic differences. |
| فهرسة مساهمة: | Keywords: OAD; T2D; Type 2 diabetes; interindividual differences; oral antidiabetic drugs |
| المشرفين على المادة: | 0 (Hypoglycemic Agents) 0 (Insulin) 9100L32L2N (Metformin) |
| تواريخ الأحداث: | Date Created: 20180328 Date Completed: 20190201 Latest Revision: 20190201 |
| رمز التحديث: | 20240628 |
| DOI: | 10.2217/pgs-2017-0195 |
| PMID: | 29580198 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 1744-8042 |
|---|---|
| DOI: | 10.2217/pgs-2017-0195 |